Table 2
The factors associated with overall survival and disease-free survival during 5-year follow-up.
|
Characteristics | Overall survival | Disease-free survival | Hazard ratio (95% confidence interval) | Univariate analysis values | Hazard ratio (95% confidence interval) | Univariate analysis values |
| Age (≥45 y versus ≤44 y) | 1.431 (0.851–2.409) | 0.177 | 1.240 (0.812–1.894) | 0.319 | Menopausal status (postmenopausal versus premenopausal) | 1.720 (1.037–2.853) | 0.036 | 1.666 (1.097–2.532) | 0.017 | Tumor size (≥2 cm versus <2 cm) | 2.336 (1.381–3.950) | 0.002 | 1.885 (1.236–2.875) | 0.003 | Tumor-mode-metastasis stage (III versus I, II) | 2.112 (1.270–3.514) | 0.004 | 1.787 (1.166–2.741) | 0.008 | Lymph node status (positive versus negative) | 2.817 (1.656–4.790) | <0.001 | 2.328 (1.521–3.563) | <0.001 | Histologic grade (III versus I, II) | 2.453 (1.451–4.148) | 0.001 | 2.010 (1.318–3.067) | 0.001 | Nuclear grade (III versus I, II) | 2.277 (1.347–3.851) | 0.002 | 1.853 (1.215–2.827) | 0.004 | Estrogen receptor status (negative versus positive) | 2.695 (1.585–4.582) | <0.001 | 2.188 (1.432–3.343) | <0.001 | Progesterone receptor status (negative versus positive) | 2.098 (1.247–3.532) | 0.005 | 1.753 (1.151–2.671) | 0.009 | Intermedin (high versus low) | 5.438 (3.029–9.763) | <0.001 | 4.885 (3.084–7.739) | <0.001 |
|
|
Univariate Cox’s regression analysis was used to calculate the Hazard ratio and 95% confidence interval.
|